Introduction: Mineral bone disorder (MBD) is a major complication of chronic kidney disease (CKD). Aim was to evaluate Fibroblast Growth Factor (FGF-23); a phosphaturic hormone, identified as a regulator of calcium-phosphorus metabolism, in dialytic CKD patients.Methods: Dialytic CKD (CKD stage 5) patients (n=48) at recruitment were compared with age matched controls (N=66) and at six months for different indicators of bone metabolism and FGF-23 levels.Results: Phosphorus (p=0.001), calcium-phosphorus product (p=0.001), intact Parathyroid hormone (p=0.001), intact-FGF-23 ( p=0.001) and C-terminal-FGF-23 (p= 0.001) levels in dialytic CKD patients were significantly higher than in their age matched controls. 1,25 (OH)2D levels were almost nil in these patients and 25(OH)D were significantly lower (p=0.01) as compared to the controls. Phosphorus and intact-FGF-23 were significantly correlated (Spearman correlation rs=0.317, p=0.028) in dialytic CKD group. These CKD stage 5 patients were on regular calcium, vitamin D and phosphate binder treatment. Follow-up study demonstrated significant reduction in phosphorus (p=0.001), increase in 25(OH)D (p = 0.001) and 1,25(OH)2D. iFGF-23 decreased marginally while there was no change in C-terminal FGF-23 levels at six months in dialytic CKD patients as compared to their recruitment levels.
Conclusion:Marked accumulation of inactive C-terminal FGF-23 might provide new insights in understanding the role of FGF-23 and hyperphosphatemia in CKD stage-5 patients.